<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799612</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0018</org_study_id>
    <secondary_id>NCI-2023-02650</secondary_id>
    <nct_id>NCT05799612</nct_id>
  </id_info>
  <brief_title>Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma</brief_title>
  <official_title>Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Cures 4 Kids</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients&#xD;
      with cutaneous angiosarcoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      •To determine the safety, toxicity, and feasibility of delivering autologous dendritic cells&#xD;
      (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head &amp; neck angiosarcoma&#xD;
      as adjuvant therapy.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      • To assess the recurrence free survival and overall survival in treated patients in order to&#xD;
      make initial assessment of activity of this therapeutic approach&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
      • To quantitate immune responses in patients who receive autologous DCs loaded with tumor&#xD;
      lysate plus mRNA&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0</measure>
    <time_frame>through study completion; an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation/Deescalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 3 doses of the vaccine (each vaccine is given 2 weeks apart). The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given by IV (vein)</description>
    <arm_group_label>Dose Escalation/Deescalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA plus Lysate-loaded Dendritic Cell Vaccine</intervention_name>
    <description>Given by IV (vein)</description>
    <arm_group_label>Dose Escalation/Deescalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGYLATED-INTERFERON ALPHA-2A</intervention_name>
    <description>Given by IV (vein)</description>
    <arm_group_label>Dose Escalation/Deescalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given by IV (vein)</description>
    <arm_group_label>Dose Escalation/Deescalation</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>NeupogenTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed cutaneous head &amp; neck angiosarcoma deemed to be&#xD;
             potentially resectable and who are deemed to be good candidates for postoperative&#xD;
             therapy with radiation and study treatment.&#xD;
&#xD;
          2. Should be willing to undergo biopsy to provide fresh frozen tumor tissue for use in&#xD;
             the creation of the vaccine.&#xD;
&#xD;
          3. 18 years of age or older and able to provide informed consent.&#xD;
&#xD;
          4. Adequate kidney, liver, bone marrow function, and immune function, as follows:&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 gm/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3&#xD;
&#xD;
               -  Lymphocytes ≥ 500 cells/mm3&#xD;
&#xD;
               -  Platelet count ≥ 75,000 /mm3&#xD;
&#xD;
               -  CD4+ T-cell counts ≥ 200/mm3&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) &gt; 60 mL/min/m2&#xD;
&#xD;
                    -  For males = (140 - age[years]) x (body weight [kg]) (72) x (serum creatinine&#xD;
                       [mg/dL]&#xD;
&#xD;
                    -  For females = 0.85 x male value&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN),&#xD;
&#xD;
               -  Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) ≤ 2.5&#xD;
                  times the ULN&#xD;
&#xD;
               -  TSH range between 0.4 - 4.0 mIU / L&#xD;
&#xD;
               -  aPTT or INR ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy. If&#xD;
                  receiving anticoagulant therapy, patient is eligible as long as prothrombin time,&#xD;
                  international normalized ratio (INR), or activated partial thromboplastin time is&#xD;
                  within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          5. ECOG performance status ≤ 2.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Locally advanced tumors deemed unresectable and/or metastatic tumors&#xD;
&#xD;
          2. Received live vaccines within 30 days prior to the first dose of trial treatment and&#xD;
             while participating in the trial. Examples of live vaccines include, but are not&#xD;
             limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever,&#xD;
             rabies, BCG, and typhoid vaccine.&#xD;
&#xD;
          3. Uncontrolled HIV infection with CD4+ &lt;200 c ells/µl or active HBC or HCV disease that&#xD;
             requires antiviral therapy.&#xD;
&#xD;
          4. Need for concurrent therapy with corticosteroids or any systemic immunosuppressive&#xD;
             agents during the vaccination phase of the study.&#xD;
&#xD;
          5. History of systemic autoimmune disease&#xD;
&#xD;
          6. Female patients who are pregnant, breast feeding, or of childbearing potential without&#xD;
             a negative pregnancy test prior to baseline. Male or female patients of childbearing&#xD;
             potential unwilling to use contraceptive precautions (refer Table 1) throughout the&#xD;
             trial and 3 months following discontinuation of study treatment. Post-menopausal women&#xD;
             must be amenorrheic for at least 12 months to be considered of non-childbearing&#xD;
             potential. Women of childbearing potential must have a negative serum pregnancy test&#xD;
             prior to the first treatment.&#xD;
&#xD;
          7. Concurrent participation on another therapeutic clinical trial.&#xD;
&#xD;
          8. Patients unwilling or unable to comply with the protocol or provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinod Ravi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vinod Ravi, MD</last_name>
    <phone>(713) 792-1641</phone>
    <email>vravi@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Vinod Ravi, MD</last_name>
      <phone>713-792-1641</phone>
      <email>vravi@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Vinod Ravi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 23, 2023</study_first_submitted>
  <study_first_submitted_qc>March 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 23, 2023</last_update_submitted>
  <last_update_submitted_qc>March 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

